Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Assets Average (2020 - 2026)

Nurix Therapeutics (NRIX) has disclosed Assets Average for 7 consecutive years, with $662.1 million as the latest value for Q1 2026.

  • Quarterly Assets Average rose 3.1% to $662.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $662.1 million through Feb 2026, up 3.1% year-over-year, with the annual reading at $678.7 million for FY2025, 32.44% up from the prior year.
  • Assets Average for Q1 2026 was $662.1 million at Nurix Therapeutics, up from $605.3 million in the prior quarter.
  • The five-year high for Assets Average was $662.1 million in Q1 2026, with the low at $329.4 million in Q3 2023.
  • Average Assets Average over 5 years is $474.9 million, with a median of $438.0 million recorded in 2022.
  • The sharpest move saw Assets Average fell 24.23% in 2023, then skyrocketed 92.2% in 2025.
  • Over 5 years, Assets Average stood at $438.0 million in 2022, then decreased by 24.23% to $331.9 million in 2023, then skyrocketed by 78.21% to $591.5 million in 2024, then rose by 2.34% to $605.3 million in 2025, then grew by 9.39% to $662.1 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $662.1 million, $605.3 million, and $557.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.